Speaker
Chimeric antigen receptor T-cell (CAR-T) therapy targeting the surface receptor CD19 (CAR19) is a potent treatment option for patients with relapsed or chemotherapy-refractory B cell malignancies. Unfortunately, cancer continues to progress in a large subset of these patients due to changes in CD19 presentation on cancer cells.
To eliminate malignant B cells with low CD19 levels, researchers have developed CAR therapies that target the B-cell specific cell surface molecule CD22. While sequential CAR therapy has shown limited success, scientists have now developed a bispecific CAR T-cell that simultaneously targets CD19 and CD22.
In this webinar brought to you by IsoPlexis, David Miklos will discuss recent advances in bispecific CAR-T therapy development and critical functional biomarkers for characterizing CAR-T product quality.
Available On Demand Now |
Today's Clinical Lab
1000 N West Street, Suite 1200
Wilmington, DE, USA 19801
Toll Free: 888.788.0328 | Phone: 705.528.6888
Email: privacy@clinicallab.com
©2022 Today's Clinical Lab®
All Rights Reserved
Terms Of Use | Privacy Policy